BioSpace News Archive

In essence, a good interview often comes down to “likeability” and if you’re able to establish a friendly rapport with the interviewer(s). Keep these 5 highly effective rapport-building techniques in mind as you interview.

Investments from Merck KGaA, Beacon Pharmaceuticals and Genomenon will provide new jobs for local economies.

It’s not exactly breaking news that biopharma companies are increasingly turning toward machine learning and artificial intelligence (AI) to improve drug development. What is big news is how resoundingly it might improve on traditional methods.

Today, EirGenix, Inc. (6589) held its opening ceremony to commemorate the launch of its new ‘Protein Drug Commercial Mass Production Plant’ in Hsinchu (Zhubei) Biomedical Park

On Feb. 12, a U.S. Food and Drug Administration (FDA) advisory committee will debate whether to recommend Johnson & Johnson’s esketamine spray for major depression. It may be an uphill battle, although any positive results in this extremely difficult-to-treat patient population will no doubt be taken into account.

Alexander (Sasha) Opotowsky, associate professor at Harvard Medical School and a cardiologist at Boston Children’s Hospital and Brigham and Women’s Hospital took time out to speak with BioSpace about advances in heart health, congenital heart disease (CHD), biopharma, and the Adult Congenital Heart Association (ACHA).

Despite having achieved a record net sales of $477 million driven by the success of its powerhouse medication Adcetris in 2018, as well as a 58 percent increase in sales during the fourth quarter in comparison to the previous year, Seattle Genetics stock fell as the results did not meet analysts’ expectations.

The idea of swallowing a needle seems like a very bad idea. But a research team at MIT has developed a capsule about the size of a blueberry that holds a tiny needle that, after being swallowed, injects insulin into the stomach.

Gossamer Bio has been the poster child for biotech companies struggling with IPO launches during the shutdown.

Based in Lexington, Mass. and Amsterdam, The Netherlands, uniQure updated its Phase IIb trial of AMT-061 in hemophilia B. AMT-061 is an AAV5-based gene therapy that contains a FIX-Padua variant, meaning a patent-protected form of Factor IX, the missing or insufficient protein that results in the disease.